Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says AnalystBenzinga • 08/09/24
Merck to buy experimental drug targeting B-cell diseases for up to $1.3 billionMarket Watch • 08/09/24
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon BiopharmaceuticalBusiness Wire • 08/09/24
Merck says it's discontinuing a late-stage trial of a lung cancer treatment after high number of adverse eventsMarket Watch • 08/08/24
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung CancerBusiness Wire • 08/08/24
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070Business Wire • 08/06/24
Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and OpportunitiesBenzinga • 08/05/24
Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help MarginsSeeking Alpha • 07/31/24
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS ViewZacks Investment Research • 07/30/24
Merck Posts Stronger-Than-Expected Results, But Outlook Falls ShortInvestors Business Daily • 07/30/24